Thirty. That is the total number of human beings who have been studied in published clinical research on BPC-157, the most popular peptide the FDA's Pharmacy Compounding Advisory Committee will review when it convenes on July 23 in Silver Spring, Maryland. Sixteen received knee injections in a retrospective case series with no control group. Twelve received bladder injections for interstitial cystitis in an uncontrolled pilot study at a private clinic in Florida. Two received intravenous infusions in a safety study that measured whether the peptide would kill them over three days. It did not. That is the complete published human evidence base for a compound that millions of Americans are already injecting, that Health Secretary Robert F. Kennedy Jr. has publicly endorsed, and that Leerink Partners estimates could anchor a $2.2 billion telehealth market by next year.
We audited the published clinical evidence for all seven peptides on the FDA's July 23-24 agenda. The results are bleak.
The Evidence Audit
The FDA will review seven peptide molecules across two days: BPC-157, TB-500, KPV, and MOTs-C on July 23, followed by Emideltide (DSIP), Semax, and Epitalon on July 24. For each, we searched PubMed, ClinicalTrials.gov, and the Cochrane Library for published human clinical data of any design, including case series, pilot studies, and pharmacokinetic trials. We excluded animal studies, in vitro work, and preprints that had not undergone peer review.
| Peptide | FDA Use Evaluated | Published Human Studies | Total Human Participants | Randomized Controlled Trials | FDA-Approved Indications |
|---|---|---|---|---|---|
| BPC-157 | Ulcerative colitis | 3 (knee pain case series, IC pilot, IV safety) | 30 | 0 | 0 |
| TB-500 | Wound healing | 0 | 0 | 0 | 0 |
| KPV | Wound healing, inflammation | 0 | 0 | 0 | 0 |
| MOTs-C | Obesity, osteoporosis | 1 (Phase 1B safety) | 20 | 0 | 0 |
| Emideltide (DSIP) | Opioid withdrawal, insomnia, narcolepsy | ~12 (mostly 1980s-90s, small) | ~300 | 2-3 (small, decades old) | 0 |
| Semax | Cerebral ischemia, migraine | Several (Russian literature) | ~500 | 2-3 (Russian, limited access) | 0 in US (approved in Russia) |
| Epitalon | Insomnia | 2-3 (Russian, elderly cohorts) | ~100 | 0-1 (unclear methodology) | 0 |
BPC-157 is marketed for everything from torn ACLs to gut healing to traumatic brain injury. The three published human studies examined knee pain, bladder inflammation, and basic IV safety. None studied ulcerative colitis, the indication the FDA is actually evaluating. TB-500 and KPV have zero published human data of any kind. Not small studies. Not bad studies. None.
The picture is marginally better for Semax and Emideltide, which have decades of research from Soviet and Russian institutions. Semax is approved in Russia for stroke and cognitive disorders. But the Russian studies are difficult to access, inconsistently translated, and conducted under regulatory standards that differ substantially from FDA requirements. Epitalon's champion, the late Russian gerontologist Vladimir Khavinson, published studies in elderly cohorts showing melatonin normalization, but the methodology of those trials does not meet Western peer review standards for randomization or blinding.
The Original Math: Evidence Per User
Here is a calculation nobody has run. Google Trends data shows BPC-157 search interest in the United States increased 840% between January 2022 and June 2026. Protocole, a peptide telehealth startup, raised $6 million in April 2026 and charges $200 to $300 per peptide with clinician oversight. Next Health, a chain of longevity clinics, told The Wall Street Journal it resumed offering BPC-157 after it had been restricted. Mino, another startup, purchased a compounding factory in South Carolina specifically for peptide production. If we conservatively estimate that 500,000 Americans have used BPC-157 at least once in the past two years, and 30 total humans have been studied in published research, that yields a ratio of one studied human for every 16,667 users. Aspirin, by comparison, had been studied in trials enrolling over 100,000 participants before it became an over-the-counter standard. That is a 3,300-fold difference in evidence density.
For TB-500, the ratio is mathematically undefined. Division by zero. The denominator of published human participants is literally nothing, yet the compound is so widely used that Joe Rogan discussed combining it with BPC-157 on a podcast that reaches 11 million listeners per episode, calling the combination "the Wolverine stack." TB-500 is banned by the World Anti-Doping Agency. It has never been tested in a single published human trial.
What the Grey Market Actually Looks Like
Christopher Mendias, a sports medicine researcher at the Performance Medicine Institute in Phoenix who fields four to five daily patient questions about peptides, recently published a preprint analyzing grey-market peptide quality. His findings: an estimated 40% to 75% of grey-market peptide samples fail to meet even two of the twelve basic pharmaceutical safety standards that any drug at Walgreens would pass. Roughly 15% of samples contained measurable endotoxin contamination, bacterial toxins that can trigger fever, organ damage, and sepsis when injected.
"What's fascinating to me," Mendias told Medscape, "is a lot of the same patients that talk about peptides are so concerned with PFAS and BPA in their water and all their impurities, and they are living a 'my body is a temple' lifestyle, but are really interested in this random peptide that has no safety data and very little purity data plus no contamination data, and they want to put it in their bodies."
The supply chain is simple and largely unregulated. Most grey-market peptides originate from Chinese synthesis labs, where production costs are a fraction of pharmaceutical-grade manufacturing. They are sold online labeled "for research purposes only" or "not for human use." Social media influencers demonstrate injection techniques. Reddit threads provide dosing protocols. Telegram and WhatsApp groups coordinate bulk purchases. The Associated Press reported that CBS News found licensed compounding pharmacies, unlicensed online vendors, and med spas all operating in the same market. Public Citizen documented that the FDA issued warning letters to 14 peptide vendors since December 2024, but 11 continued advertising and 8 continued selling.
Mendias described two patients in their late 20s who used PT-141, a grey-market version of the FDA-approved bremelanotide. Both experienced erectile dysfunction within a day, the opposite of the marketed effect. One developed what Mendias called "crushing depression" that was difficult to recover from. Both experienced patchy skin lightening. Another patient reported blood in his urine after starting BPC-157 and was so convinced of its healing properties that he initially refused to consider the peptide as the cause.
The Regulatory Collision
Under Biden, the FDA added these peptides to Category 2, a restricted list barring compounding pharmacies from manufacturing them, citing immunogenicity, toxicity, and impurity concerns. The agency's pharmacy advisory committee voted overwhelmingly that they did not meet safety criteria. That was 2023.
Under Kennedy, the peptides have been removed from the restricted list and placed before a reconstituted advisory committee. "This action begins to restore regulated access and will immediately begin shifting demand away from the black market," Kennedy wrote on social media. He told Joe Rogan, "I'm a big fan of peptides. I've used them myself and with really good effect on a couple of injuries."
Kennedy's stated logic has a surface appeal. If millions are already injecting grey-market peptides of unknown purity, allowing compounding pharmacies to produce them under state regulation would at least improve quality control. Scott Brunner of the Alliance for Pharmacy Compounding acknowledged the tension: "Compounding pharmacies are being hammered by patients and prescribers to prepare these peptide drugs, and legally, they can't do it. Not yet, anyway. And that is stimulating the illicit, non-pharmacy actors in the gray market."
But Pinchas Cohen, the USC gerontology dean who discovered MOTs-C and has testified before the FDA as an expert on peptide therapeutics, sees a deeper problem. The current advisory committee "are all pharmacists," Cohen told Medscape. "I don't want to disrespect them, but they're not physicians. They understand compounding. But to decide that something is good enough to start giving away, there should be doctors and drug development experts." He also noted that adding peptides to the compounding list would not eliminate the grey market: "Even if they got some of these produced by reputable compounders in the US, the same sources will likely persist, because Chinese producers are less than half the price."
The Strongest Case For
The preclinical evidence, particularly for BPC-157, is genuinely striking. A 2025 systematic review of 36 studies spanning 1993 to 2024 found that BPC-157 consistently promoted healing across muscle, tendon, ligament, and bone injury models in animals. It activates VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promotes angiogenesis and fibroblast activity, engages ERK1/2 signaling, and exerts anti-inflammatory effects. A lethal dose has never been reached in toxicological studies. Phase II ulcerative colitis trials conducted in the early 2000s reported no adverse effects, though the results were never published in full.
The argument from preclinical promise is not nothing. It is also not enough. Mendias pointed out that virtually all BPC-157 research comes from a single Croatian laboratory, and "a positive effect on everything it's ever been studied in" is itself a red flag. MOTs-C showed safety in a 20-person Phase 1B trial, but Cohen said the project stalled because effective dosing required daily or twice-daily injections at volumes impractical for drug development. Semax has the strongest regulatory precedent, having been approved in Russia for decades, but no Western regulatory body has reviewed it.
The Strongest Case Against
Eric Topol of Scripps Research Translational Institute was direct: "I think this is a disaster in the works. These peptides have no data to support their safety and efficacy." Peter Lurie, former FDA official and president of the Center for Science in the Public Interest, was sharper: "I don't see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market." He added that he does not believe the current review is "an honest investigation of whether these products should be compounded," given Kennedy's public enthusiasm.
The regulatory concern is systemic, not specific to any single peptide. If the FDA approves compounding access based on preclinical data and anecdotal evidence from a Health Secretary who uses the products himself, it establishes a precedent that could apply to hundreds of other compounds with similar evidence profiles. Phil Dawson, former president of the American Peptide Society, noted that the simplicity of peptide synthesis means anyone can "order one up" and receive "a little white powder, and that may or may not be that peptide." Allowing compounding would not raise the floor of the grey market; it would lower the ceiling of the regulatory system.
Limitations
Our evidence audit covers published, peer-reviewed literature accessible through PubMed and Cochrane as of June 2026. Russian-language studies on Semax, Emideltide, and Epitalon may include additional data not captured in English-language databases; we note this gap rather than claim comprehensive coverage of the Russian literature. The user estimate of 500,000 BPC-157 users is our extrapolation from market data, telehealth company disclosures, and search trend analysis; no population-level survey of peptide use in the United States has been conducted. The Mendias grey-market quality study was published as a preprint and has not undergone peer review. The $2.2 billion market estimate from Leerink Partners is a forward-looking projection based on telehealth adoption models, not observed revenue.
What You Can Do
If you are currently using grey-market peptides, tell your doctor. This is not a moral judgment. Mendias explicitly tells his patients: "If you choose to use them and something happens that you need help with, come see us. We're not going to judge you for it." The culture of silence around peptide side effects, driven by social media communities that treat any negative report as heresy, means adverse events are being systematically underreported. Your doctor cannot help with what they do not know about.
If you are considering peptides for injury recovery or longevity, understand the evidence hierarchy you are operating in. BPC-157 has three published human studies with 30 total participants and no randomized controlled trials. That places it below the evidence threshold that any competent physician would accept for prescribing a new drug. The fact that your favorite podcast host swears by it is not a clinical trial. Ask yourself whether you would take a cancer drug with this evidence base. If the answer is no, the question is why you are willing to inject this one.
If you are a clinician being asked about peptides daily, the FDA docket (FDA-2025-N-6895) closes on July 22. Public comments are being accepted. The committee that reviews these compounds currently has vacancies that Kennedy could fill before the hearing. If you have clinical expertise on peptide safety, this is the venue where it matters.
The Bottom Line
In 26 days, an FDA advisory committee will consider whether seven peptides should be legal for compounding pharmacies to manufacture and sell with a prescription. The combined published human evidence for the four peptides under review on July 23 totals three studies and 50 participants. No randomized controlled trial has ever been conducted on BPC-157, TB-500, or KPV. The grey market these compounds currently inhabit delivers products that fail basic pharmaceutical standards at rates between 40% and 75%, with 15% containing bacterial endotoxins. The market opportunity is projected at $2.2 billion. The Health Secretary who initiated the review calls himself "a big fan." The scientists who discovered these molecules are asking for research funding, not deregulation. Maliha Zahid, a peptide researcher at the Mayo Clinic, summarized the position of the scientific community in one sentence: "FDA approval is the stamp I would look for before using any peptide in any of my patients." Whether that standard survives July 23 is no longer a scientific question.